PA
NTLA icon

Perceptive Advisors’s Intellia Therapeutics NTLA Stock Holding History

Perceptive Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-14,673
Closed -$192K – 189
2016
Q4 		$192K Hold
14,673
– – 0.01% 144
2016
Q3 		$250K Sell
14,673
-327
-2% -$6.33K 0.02% 158
2016
Q2 		$320K Buy
+15,000
New +$399K 0.02% 138

Other funds holding NTLA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Perceptive Advisors's NTLA Position: Q1 2017 in Review

Perceptive Advisors sold out of Intellia Therapeutics (NTLA) in Q1 2017, closing a stake of 14,673 shares — an estimated $192K sold.

Perceptive Advisors first reported a position in NTLA in Q2 2016 and held it in 3 quarters. The position peaked at $320K in Q2 2016. 76 funds tracked by Wall St. Rank hold NTLA as of Q1 2017.

  • Perceptive Advisors reported no remaining Intellia Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Perceptive Advisors sold 14,673 Intellia Therapeutics shares in Q1 2017, an estimated $192K.
  • Perceptive Advisors first reported a position in Intellia Therapeutics in Q2 2016 and held it in 3 quarters.
  • Perceptive Advisors's Intellia Therapeutics position peaked at $320K in Q2 2016.
  • 76 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2017.

Based on Perceptive Advisors's 13F filing for Q1 2017, filed 15 May 2017.